A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

In Phase A, members will obtain various doses and schedules of oral ABBV-744 tablet to recognize Secure dosing program. More participants will be enrolled within the determined monotherapy dosign regimen. In Phase B, individuals will receive oral ruxolitinib and ABBV-744 will be offered as "add-on" therapy. In Section C, participants will get ABBV-